- Diurnal said Thursday headline data from its European Phase III trial showed that its congenital adrenal hyperplasia treatment was not superior to standard-of-care, failing to meet its primary objective.

Given the strong Phase II data, this outcome was unexpected, the company said.

The full data was now being analysed.

At 8:57am: [LON:DNL] Diurnal Group Plc share price was 0p at 37.5p

Story provided by